Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities.

Gojo J, Pavelka Z, Zapletalova D, Schmook MT, Mayr L, Madlener S, Kyr M, Vejmelkova K, Smrcka M, Czech T, Dorfer C, Skotakova J, Azizi AA, Chocholous M, Reisinger D, Lastovicka D, Valik D, Haberler C, Peyrl A, Noskova H, Pál K, Jezova M, Veselska R, Kozakova S, Slaby O, Slavc I, Sterba J.

Front Oncol. 2020 Jan 10;9:1436. doi: 10.3389/fonc.2019.01436. eCollection 2019.

2.

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G.

Eur J Cancer. 2020 Mar;127:52-66. doi: 10.1016/j.ejca.2019.12.029. Epub 2020 Jan 24.

3.

Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?

Noskova H, Kyr M, Pal K, Merta T, Mudry P, Polaskova K, Ivkovic TC, Adamcova S, Hornakova T, Jezova M, Kren L, Sterba J, Slaby O.

Cancers (Basel). 2020 Jan 17;12(1). pii: E230. doi: 10.3390/cancers12010230.

4.

Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells.

Skoda J, Neradil J, Staniczkova Zambo I, Nunukova A, Macsek P, Borankova K, Dobrotkova V, Nemec P, Sterba J, Veselska R.

Cancers (Basel). 2020 Jan 13;12(1). pii: E196. doi: 10.3390/cancers12010196.

5.

Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy.

Veselska R, Jezova M, Kyr M, Mazanek P, Chlapek P, Dobrotkova V, Sterba J.

Front Oncol. 2019 Nov 15;9:1221. doi: 10.3389/fonc.2019.01221. eCollection 2019.

6.

Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma.

Fedorova L, Mudry P, Pilatova K, Selingerova I, Merhautova J, Rehak Z, Valik D, Hlavackova E, Cerna D, Faberova L, Mazanek P, Pavelka Z, Demlova R, Sterba J, Zdrazilova-Dubska L.

Front Oncol. 2019 Nov 14;9:1169. doi: 10.3389/fonc.2019.01169. eCollection 2019.

7.

Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome.

Hlavackova E, Pilatova K, Cerna D, Selingerova I, Mudry P, Mazanek P, Fedorova L, Merhautova J, Jureckova L, Semerad L, Pacasova R, Flajsarova L, Souckova L, Demlova R, Sterba J, Valik D, Zdrazilova-Dubska L.

Front Oncol. 2019 Oct 25;9:1034. doi: 10.3389/fonc.2019.01034. eCollection 2019.

8.

Phospho-Protein Arrays as Effective Tools for Screening Possible Targets for Kinase Inhibitors and Their Use in Precision Pediatric Oncology.

Neradil J, Kyr M, Polaskova K, Kren L, Macigova P, Skoda J, Sterba J, Veselska R.

Front Oncol. 2019 Sep 20;9:930. doi: 10.3389/fonc.2019.00930. eCollection 2019.

9.

Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study.

Danhofer P, Tomečková M, Černá D, Zapletalová D, Horák O, Aulická Š, Juříková L, Domanský J, Kovalčíková P, Pavlík T, Štěrba J, Ošlejšková H.

Seizure. 2019 Nov;72:1-10. doi: 10.1016/j.seizure.2019.08.007. Epub 2019 Aug 15.

PMID:
31521834
10.

DICER1 Syndrome.

Hořínová V, Drábová K, Nosková H, Bajčiová V, Šoukalová J, Černá L, Hůrková V, Slabý O, Štěrba J.

Klin Onkol. 2019 Summer;32(Supplementum2):123-127. doi: 10.14735/amko2019S123.

PMID:
31409088
11.

Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario.

Kyr M, Polaskova K, Kuttnerova Z, Merta T, Neradil J, Berkovcova J, Horky O, Jezova M, Veselska R, Klement GL, Valik D, Sterba J.

Front Oncol. 2019 Jul 17;9:644. doi: 10.3389/fonc.2019.00644. eCollection 2019.

12.

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.

Dobrotkova V, Chlapek P, Jezova M, Adamkova K, Mazanek P, Sterba J, Veselska R.

PLoS One. 2019 Jun 12;14(6):e0218269. doi: 10.1371/journal.pone.0218269. eCollection 2019.

13.

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, Minard-Colin V, Adamson P, Marshall LV, Balakumaran A, Benettaib B, Bhargava P, Bollard CM, Bolotin E, Bomken S, Buechner J, Burkhardt B, Caron H, Copland C, Demolis P, Egorov A, Farhan M, Zugmaier G, Gross T, Horton-Taylor D, Klapper W, Lesa G, Marcus R, Miles RR, Nottage K, Pacaud L, Ricafort R, Schrappe M, Sterba J, Vezan R, Weiner S, Kim SY, Reaman G, Vassal G.

Eur J Cancer. 2019 Mar;110:74-85. doi: 10.1016/j.ejca.2019.01.013. Epub 2019 Feb 14.

PMID:
30772656
14.

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R.

BMC Cancer. 2018 Nov 1;18(1):1059. doi: 10.1186/s12885-018-4966-5. Review.

15.

Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis.

Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, Noskova H, Sterba J, Veselska R.

Int J Mol Sci. 2018 Sep 1;19(9). pii: E2599. doi: 10.3390/ijms19092599.

16.

Host-dependent variables: The missing link to personalized medicine.

Demlova R, Zdrazilova-Dubska L, Sterba J, Stanta G, Valik D.

Eur J Surg Oncol. 2018 Sep;44(9):1289-1294. doi: 10.1016/j.ejso.2018.04.014. Epub 2018 Apr 26. Review.

PMID:
29735363
17.

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids.

Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R.

Int J Mol Sci. 2018 Jan 3;19(1). pii: E132. doi: 10.3390/ijms19010132. Review.

18.

Clinicopathological correlation of tumor-associated macrophages in Ewing sarcoma.

Handl M, Hermanova M, Hotarkova S, Jarkovsky J, Mudry P, Shatokhina T, Vesela M, Sterba J, Zambo I.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Mar;162(1):54-60. doi: 10.5507/bp.2017.049. Epub 2017 Nov 21.

19.

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J.

Pediatr Hematol Oncol. 2017 Aug;34(5):308-319. doi: 10.1080/08880018.2017.1373314. Epub 2017 Nov 17.

PMID:
29148865
20.

Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD.

Cancer Cell. 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005.

Supplemental Content

Loading ...
Support Center